US Pharm. 2007;1:8.
Express Scripts Looks to
Acquire Caremark Rx
St. Louis--Express
Scripts, a prescription benefits management (PBM) company serving more than 50
million members, is proposing to acquire all of the outstanding shares of
Caremark Rx, Inc., a pharmaceutical services company providing drug benefits
to over 2,000 health plan sponsors and their participants. The transaction is
said to be valued at $26 billion. The Express Scripts offer comes on the heels
of a proposed acquisition of Caremark by CVS Corporation. Based on stock
prices at press time, the Express Scripts offer represents a 21.5% premium
over what CVS proposed. According to Caremark, it has "executed a merger
agreement with CVS Corporation which provides for the combination of the two
companies in a transaction structured as a merger of equals." The company said
its Board of Directors will review the terms of the Express Scripts proposal
"in a manner consistent with its obligations under the CVS merger agreement
and applicable Delaware law." A statement released by Express Scripts said it
believes the complementary nature of the two companies will create an
industry-leading PBM uniquely positioned to generate substantial stockholder
value.
UCSF Pharmacy School Receives
Grant for Medicare Part D Outreach
San Francisco--The
University of California, San Francisco (UCSF), School of Pharmacy received a
$3.7 million grant from the Amgen Foundation to fund an innovative program
that will help elderly Californians learn more about and select from Medicare
prescriptions drug plans (PDPs). There are currently more than 70 PDPs in
California, most of which are Medicare Part D plans. The initiative, titled Partners
in D, is a three-and-a-half-year program that will train pharmacy
students, who will in turn educate other health care professional students
about Medicare Part D and then move out into the community to provide
one-on-one assistance to Medicare-eligible seniors.
Pfizer Sells Consumer Healthcare
Business
New York City--Pfizer
Inc. has sold its Pfizer Consumer Healthcare business to Johnson & Johnson for
$16.6 billion. According to Jeffrey Kindler, Pfizer Chairman and CEO, the
proceeds from the sale will offer the company "flexibility to invest in the
growth of our core pharmaceutical business." He emphasized that Pfizer is
"committed to pursuing new products and technologies that complement our
internal development programs and represent attractive, strategic
opportunities to grow and meet unmet medical needs."
New Web Site Exclusively for
Pharmacy Directors Launched
Woodbridge, Va.--PharmacyDirectors.com
is a new Web site with a mission to assist pharmacy directors in daily
operational challenges by providing comprehensive and practical information,
as well as encouraging peer-to-peer communication among directors, via
bulletin board forums. Because it is Internet-based, the Web site allows
pharmacy directors to interact with colleagues worldwide, sharing information
on personal experiences. According to Arash T. Davestani, PharmD, MHA,
Managing Editor of PharmacyDirectors.com, a key area of the Web site is
devoted to helping the directors cope with cost-containment issues in an
environment of rising drug costs. It will also allow them to keep abreast of
compliance issues and changes in the regulatory landscape, including JCAHO
guidelines. The site has already been visited by pharmacy directors from all
50 U.S. states and 66 different countries. It is supported by B. Braun
Medical, Inc.
To comment on this article,
contact editor@uspharmacist.com.